Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tysabri prospective fatigue study in relapsing-remitting multiple sclerosis
2008-008065-35Phase 4Completed
- Sponsor
- Biogen
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Change in fatigue associated with multiple sclerosis. Started Dec 2008; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2008-008065-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008065-35.